Alzheimer’s Foundation of America Appoints Dr. Peter Davies to its Medical, Scientific and Memory Screening Advisory Board
The Alzheimer’s Foundation of America (AFA) has appointed Dr. Peter Davies, one of the world’s top Alzheimer’s disease researchers, to its Medical, Scientific and Memory Screening Advisory Board. The Board is comprised of leading experts in the care, research and treatment of Alzheimer’s disease.
“We are very excited to welcome Dr. Davies to our Medical, Scientific and Memory Screening Advisory Board,” said Charles J. Fuschillo, Jr., AFA’s President and Chief Executive Officer. “He is an extraordinarily intelligent, dedicated hard working professional who has done remarkable work in researching the development of new treatments and diagnostic tests for Alzheimer’s disease. His insight, knowledge and input will be extremely helpful as we continue working to improve the level of care and treatment, and ultimately find a cure, for Alzheimer’s disease.”
“Dr. Davies has spent more than three decades researching Alzheimer’s disease and working towards finding a treatment and cure,” said Bert E. Brodsky, AFA’s Founder and Board Chairman. “His professional experience in the field and passion for helping others will make him a valuable addition to AFA’s Medical, Scientific and Memory Screening Advisory Board.”
“I am honored to serve on the Medical Advisory Board of AFA,” said Dr. Davies. “I am full of admiration for the job that AFA does, and for the people who have dedicated their time and talents to this important work.”
Peter Davies, Ph.D., is the director of the Litwin-Zucker Center for Alzheimer’s Disease at The Feinstein Institute for Medical Research. He is also a professor of pathology and neuroscience at Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. For more than 35 years, Dr. Davies’ research has focused on the biochemistry of Alzheimer’s disease. This includes exploring the underlying causes of some of the more disturbing behaviors associated with Alzheimer’s disease, including agitation, hallucinations and aggression, as a means for identifying ways to treat them. His team’s main area of research has been searching for the reasons why a normal brain becomes a brain with Alzheimer’s disease.
Dr. Davies has published more than 250 research papers. He has received numerous awards for his research, including the Lifetime Achievement Award from the International Congress on Alzheimer’s Disease (ICAD), the City of New York Liberty Medal, the Ciba Geigy/Drew Award, the Metropolitan Life Award, and two MERIT awards from the National Institutes of Health.
AFA relies on members of its Medical, Scientific and Memory Screening Advisory Board for expert insight and opinions on scientific issues surrounding Alzheimer’s disease and related dementias, as well assistance with the development of AFA policies, programs and advocacy efforts related to research and care.
